Chlamydia trachomatis and Mycoplasma genitalium prevalence and associated factors among women presenting to a pregnancy termination and contraception clinic, 2009–2019. (29th March 2021)

• Record Type: Journal Article
• Authors: Shilling, Hannah S; Garland, Suzanne M; Costa, Anna-Maria; Marceglia, Alex; Fethers, Katherine; Danielewski, Jennifer; Murray, Gerald; Bradshaw, Catriona; Vodstrcil, Lenka; Hocking, Jane S; Kaldor, John; Guy, Rebecca; Machalek, Dorothy A
• Is Part Of: Sexually transmitted infections. Volume 98:issue 2(2022)
• Page Start: 115
• Page End: 120
• Publication Date: 2021-03-29
• Subjects: chlamydia trachomatis -- M genitalium -- sexual health -- antibiotic resistance -- pelvic inflammatory disease; Sexually transmitted diseases -- Periodicals; HIV infections -- Periodicals; 616.951005
• DOI: 10.1136/sextrans-2020-054695
• Languages: English
• ISSNs: 1368-4973

Abstract

Abstract : Background: Risk of pelvic inflammatory disease associated with Chlamydia trachomatis and Mycoplasma genitalium is increased after termination of pregnancy (TOP) and may be increased after insertion of intrauterine devices (IUDs). Screening prior to these procedures is recommended only for C. trachomatis . We examined C. trachomatis and M. genitalium prevalence and associated factors among women presenting to a pregnancy termination and contraception service over 10 years. Methods: Retrospective analysis of clinical data collected from 17 573 women aged 15–45 years in 2009–2019 and for 266 M . genitalium positive women tested for macrolide resistance-associated mutations in 2016–2019. Results: C. trachomatis and M. genitalium prevalence was 3.7% and 3.4%, respectively. In multivariable analyses, shared risk factors were younger age (p<0.001, for both C. trachomatis and M. genitalium ), socioeconomic disadvantage (p=0.045 and p=0.008, respectively) and coinfection (p<0.001, for both sexually transmitted infections), with 10.1% of C. trachomatis positive women also positive for M. genitalium . Additional risk factors were earlier year of visit (p=0.001) for C. trachomatis and for M. genitalium residing outside a major city (p=0.013). The proportion of M. genitalium infections tested between 2016 and 2019 with macrolide resistance-associated mutations was 32.7%. Conclusions: Given the high level of antimicrobial resistance and the prevalence of coinfection, testing C. trachomatis positive women for M. genitalium could be considered in this setting to prevent further spread of resistant infections. Further research is required into the causal link between M. genitalium and pelvic inflammatory disease in women undergoing TOP and IUD insertion.